Kornimate/medical-research-clean huggingface dataset:
clinical trial of zirconia and metal adhesive bridges

Conditions: Missing Teeth

Summary: adhesive bridges are becoming popular in patients with congenitally missing teeth and these are type of bridges that can be done with only minimal or with no preparation to replace the missing tooth/teeth. the best clinical gain is the minimal tooth preparation or no need for the removal of tooth substance. treatment for this type of bridges does not usually require anaesthesia. in addition, adhesive bridges can provide reasonable aesthetical outcome with minimal cost and reduced chair time. the biggest issue is that high failure rate in the long term, and gray colour shining through the metal wing cemented onto the abutment tooth. this can compromise the aesthetical outcome. the aesthetical problem can be solved by the use of zirconia all ceramic material to construct the bridge.


Eligibility criteria:
inclusion criteria: * male or female ≥ 18 years of age * has a maximum of 2 units requiring placement * is a regular dental attendee and agree to return for assessments * written subject informed consent (ic) for this protocol will be obtained prior to study enrolment. each subject will be required to sign and date the ic form prior to their participation * sound or minimally restored abutment(s) exclusion criteria: * the presence of any periodontal pocket depths equal or above 4 mm with active periodontal disease * any history of adverse reaction to clinical materials to be used in this study * they are pregnant or had serious medical condition that may interfere with the dental treatment * acquired tooth loss more than 2 units requiring replacement * participants who have parafunctional habits * severe class ii div ii cases
physiologic measure of vipn

Conditions: Chemotherapy-induced Peripheral Neuropathy

Summary: the purpose of this study is the development of a physiologic endpoint using a novel technology that would provide an objective, easy to use and more sensitive assessment of vipn in children and adolescents. the ability to more easily detect and monitor vipn, even before it is clinically evident, would facilitate optimizing the dosing of vincristine for maximal disease response while minimizing the risk of lifelong functional deficits affecting quality of life. this approach would also enable the development of specific therapies to minimize or eliminate the occurrence of vipn in children and adolescents. this is a single site study that aims to develop a novel device to evaluate and characterize vincristine-induced neuropathic pain. the investigators will enroll patients with all following the delayed intensification (di) phase of treatment. at each study visit, the investigators will evaluate the nprd as well as the tns-pv. the nprd will inform the neuropathy index which will be used to compare to the tns-pv. we anticipate a correlation between the two.


Eligibility criteria:
inclusion criteria: * 6-18 years of age at the start of the study, are receiving vincristine in di (clinical study population) and are willing and able to provide informed consent or assent to study participation. exclusion criteria: * have eye pathology which precludes pupillometry, are hemodynamically unstable, or are pregnant.
cardiac sarcoidosis response to steroids trial

Conditions: Cardiac Sarcoidosis; Sarcoidosis

Summary: there are no published clinical consensus guidelines on the treatment of cardiac sarcoidosis. corticosteroid therapy is advocated by some experts, but is based on small observational studies, with varied clinical response. objectives of this trial: * to systemically assess the response of patients with cardiac sarcoidosis, to treatment with corticosteroids * to identify the clinical predictors of response to treatment with corticosteroids * to assess the utility of imaging with pet and mri to predict response to treatment with corticosteroids * to determine the prevalence of cardiac sarcoidosis in young patients with unexplained heart block and in patients with unexplained dilated cardiomyopathy associated with ventricular tachycardia * to use the data from this pilot study to assess the need, feasibility, and sample size for a larger multicentre trial


Eligibility criteria:
inclusion criteria: * evidence of clinical cardiac sarcoidosis causing significant conduction system disease (defined as complete right bundle branch block and left axis deviation or left bundle branch block or second or third degree av block in young patients (\< 60 yrs) and/or * evidence of clinical cardiac sarcoidosis causing non-ischemic dilated cardiomyopathy and sustained ventricular tachycardia and * pet or mri imaging supporting the diagnosis of cardiac sarcoidosis exclusion criteria: * unable or unwilling to provide informed consent * history of noncompliance of medical therapy * patients with active infection * patients with active inflammatory disease not related to sarcoidosis * patients with other known causes of heart block or lv dysfunction * patients with known active malignancy * patients wwho are pregnant or lactating * patients with other indications for steroids

Keywords: cardiac sarcoidosis sarcoidosis
telerehabilitation and face-to-face rehabilitation on covid-19 survivors

Conditions: Covid19; Exercise Tolerance; Quality of Life; Lung Function; Fatigue Intensity

Summary: introduction: as this is a new disease, the short- and long-term consequences for patients with covid-19 are still unclear. the use of sedatives, as well as prolonged rest, can lead to musculoskeletal damage, including decreased muscle strength and physical function. thus, rehabilitation after this disease is a key component in continuing patient care. objective: to verify the effects of face-to-face cardiac rehabilitation and telerehabilitation on tolerance to the maximum and submaximal exercise, lung function, fatigue intensity and quality of life of covid-19 survivors. methods: this is a longitudinal, intervention study. primary outcomes will be maximum and submaximal functional capacity, intensity and impact of fatigue, while secondary outcomes will be lung function and quality of life. expected results: this work will bring important information to the scientific community and health professionals, about the best forms of intervention and its repercussions on the surviving individuals of covid-19.


Eligibility criteria:
inclusion criteria: * adults of both genders; * with a diagnosis of covid-19 confirmed by a laboratory through rt-pcr means; * have to access to the internet and some device (smartphone, computer or notebook) that allows them to participate in the call centre. exclusion criteria: * individuals with orthopaedic or neurological diseases; * individuals with difficulties in understanding and that present psychological changes that make it difficult or impossible to understand the information presented.
treatment engagement with technology-assisted treatment

Conditions: Alcoholism; Substance-related Disorders; Mentally Ill Chemical Abuse; Educational Technology

Summary: this research is being done to study whether using an internet-based program, called the therapeutic education system (tes), would be helpful for the treatment of substance use and other psychiatric problems.

tes has been shown to be helpful as substance abuse treatment in certain groups of people, mainly in the outpatient setting by using interactive modules for education. this study will expose some participants to this program while participants are hospitalized on an inpatient unit, and give the participants access to it after participants are discharged from the hospital. those participants will still receive treatment as usual, as will the control group.

Eligibility criteria:
inclusion criteria: * diagnosis of drug or alcohol problem, plus another psychiatric problem, such as depression or anxiety * drug or alcohol use in the last 30 days * proficiency in english * able to consent to study * willing to engage in outpatient treatment * willing to allow study team to contact outpatient providers exclusion criteria: * psychotic symptoms, such as hearing voices * involuntary admission
safety and tolerability of vertebral bone marrow-derived mesenchymal stem cells (bm-msc) in real world scenarios of patients with chronic kidney disease (ckd)

Conditions: Chronic Kidney Diseases

Summary: the purpose of this treatment protocol is to treat an intermediate-sized population with chronic kidney disease (ckd). protocol includes a single treatment with intravenously-delivered allogeneic bone marrow-derived mesenchymal stem cells (bm-mscs) infusion. individuals will have subsequent follow up for safety evaluations.


Eligibility criteria:
inclusion criteria * estimated glomerular filtration rate (egfr) \<60 ml/min/1.73m\^2 * hemoglobin a1c of ≤9%, if diabetes mellitus present * ability to give informed consent exclusion criteria * anemia (hemoglobin \<8.5 g/dl) * body weight \>150 kg or bmi \>50 * uncontrolled hypertension: sustained systolic blood pressure (sbp) \>160 mmhg or diastolic blood pressure (dbp) ≥100 mmhg despite maximal doses of at least 2 different classes of anti-hypertensive medications * chronic hypotension history: sustained sbp \<85 mmhg * kidney failure requiring ongoing kidney replacement therapy (hemodialysis, peritoneal dialysis, or kidney transplantation) * active immunosuppression therapy (including prednisone ≥10 mg daily) * kidney transplantation history * solid organ transplantation history * recent cardiovascular event (hospitalization for myocardial infarction, stroke, congestive heart failure (nyha class ≥iii or ejection fraction ≤30%) within 3 months or uncontrolled cardiac arrhythmias (e.g. ventricular arrhythmia, supraventricular tachycardia and bradyarrhythmia) * history of liver cirrhosis * chronic obstructive pulmonary disease or asthma requiring daily medication * history of recurring blood clotting disorder (thromboembolism; pulmonary embolism, deep venous thrombosis) requiring chronic anticoagulation therapy * pregnancy * unwilling to use contraception for at least 2 months after msc infusion if sexually active and able to become pregnant or father a child. * active malignancy * active infection (e.g. systemic or specific organ involvement such as pneumonia or osteomyelitis) * recent covid-19 infection within the last 1 month * history of hepatitis b or c (without cure), or hiv infection * history of allergic reaction to cellular products (i.e. blood transfusions, platelets) * active tobacco use * illicit drug use and excessive alcohol use * presence of psychosocial issues (e.g., uncontrolled mental illness, unpredictable childcare or eldercare responsibilities, irregular/ inflexible work schedule) that may interfere with the ability to complete all study procedures * patients anticipating prolonged travel or other physical restrictions that would prohibit return for scheduled study visits. * inability to give informed consent

Keywords: stem cells regenerative medicine mesenchymal stromal cells kidney disease kidney failure
victor - avelox® intravenous (i.v.) in acute exacerbations of chronic bronchitis

Conditions: Chronic Bronchitis; Disease Exacerbation

Summary: this study is a local, prospective, open-label, company-sponsored, non interventional, multi-center study. patients documented must suffer from an acute exacerbation of chronic bronchitis and take at least one dose of moxifloxacin injection.the primary objective is to obtain clinical effectiveness and safety data of moxifloxacin injection in the treatment of acute exacerbations of chronic bronchitis in patients in whom moxifloxacin was routinely prescribed. the secondary objective is to find out the possible correlation between the risk factors (sex, smoking, number of previous exacerbations, etc) and aecb, the different treatment effectiveness according to anthonisen classification. this study will also collect the data of pathogens by sputum culture and the defervescence time of moxifloxacin injection in treating acute exacerbations of chronic bronchitis (aecb).


Eligibility criteria:
inclusion criteria: * patients at least 18 years of age with a diagnosis of aecb treated with moxifloxacin injection with/without sequential tablet treatment exclusion criteria: * exclusion criteria must be read in conjunction with the local product information

Keywords: acute exacerbations of chronic bronchitis avelox bronchitis
effects of niv and cpap on ventilation distribution, measured by eit, during deep sedation in paediatric patients

Conditions: Respiratory Failure; Sedation; Mechanical Ventilation Complication

Summary: in patients undergoing spontaneous breathing (sb) deep sedation there is a re-distribution of ventilation towards lungs non-dependant areas (ventral areas in supine position). non-invasive ventilation (niv), offering positive pressure, should favour a better ventilation of dependant areas (dorsal areas in supine position), making ventilation more homogeneous and increasing functional residual capacity. electrical impedance tomography (eit) is a non-invasive, non-operator dependent, bedside, radiations-free diagnostic tool, feasible in paediatric patients and repeatable; it allows to study ventilation distribution, and it can measure and calculate also parameters that are related to the homogeneity of ventilation and the response to certain therapeutic maneuvers, such as anaesthesia or peep-application. uses of eit in paediatric age are described in literature, but it has never been described as being used in non-operating room anaesthesia, nor in other cases of sb deep sedation. in addition, the impact of niv on the distribution of ventilation in healthy paediatric patients undergoing deep sedation has never been described.


Eligibility criteria:
inclusion criteria: * paediatric age (from 1 to 10 years old) * asa score ≤ 2 * sedation time ≥ 30 min exclusion criteria: * asa score ≥ 3 * lung pathologies (such as asthma, bronchopulmonary dysplasia, obstructive sleep apnoea) preterm infant * severe obesity * dorso-lumbar pathologies or other bone pathologies associated with restrictive lung disease (such as scoliosis, kyphosis) * neuromuscular, mitochondrial, metabolic or chromosomal disease with hypotonia * cpap or niv treatment at home * hand-bag ventilation (hbv) during the procedure (loss of the respiratory drive) * non-total intravenous anaesthesia (tiva), adherence to the sedation protocol * implantable devices not compatible with eit (such as pace-makers and implantable cardioverter defibrillator)

Keywords: niv; cpap; eit;
pxvx0200 (cvd103-hgr) vs shanchol in mali

Conditions: Cholera

Summary: to compare the ability of a single dose of pxvx0200 at two different dose levels, to placebo to elicit a significant antibody response 14 days after vaccination, compared to baseline. to compare the ability of a single dose of pxvx0200 to a comparator vaccine shanchol, a two dose administration, to elicit antibody response by 14 days after vaccination.

currently there are two licensed inactivated vibrio oral vaccines (dukoral® \[crucell; leiden, the netherlands\] and shanchol™ \[shantha biotechnics; hyderabad, india\]) that are pre-qualified by the world health organization (who) for procurement by united nations (un) agencies. each of these vaccines requires a two-dose regimen which is difficult to implement in the face of explosive outbreaks of cholera in unsettled situations in developing countries. for this reason there is great interest in identifying a cholera vaccine that can provide rapid onset of protection following the ingestion of just a single oral dose. this phase 2 randomized, observer-blinded and subject-blinded clinical trial to be conducted in bamako, mali will assess the immunogenicity of the 10\^8 cfu versus the 10\^9 cfu formulation of paxvax-manufactured cvd 103-hgr.

Eligibility criteria:
inclusion criteria: * able to understand the study and give consent (either written or through a process that involves audio tapes explaining all aspects of the study and the consent form in local languages \[bambara and french\] followed by making a mark and signature by a literate witness) * healthy men or women, age 18 to 45 years (inclusive) without significant medical history * women of child-bearing potential must have negative urine pregnancy test at baseline, prior to vaccination. they must also be willing to use adequate birth control for the duration of the 28-day study and have additional pregnancy tests if indicated. effective methods of birth control for this study include abstinence, intrauterine device (iud), oral or depot contraceptive, or barrier plus spermicide * willingness to remain in the study area until at least 42 days after receipt of the first vaccine dose exclusion criteria: * health care workers who have direct contact with patients who are immune deficient, hiv-positive, or have an unstable medical condition * clinically significant history of immunodeficiency, cardiovascular disease, respiratory disease, endocrine disorder, liver disease, renal disease, gastrointestinal disease, neurologic illness, psychiatric disorder requiring hospitalization, current drug or alcohol abuse * history of an abnormal stool pattern or regular use of laxatives * previously received a licensed or investigational cholera vaccine * history of cholera illness

Keywords: cholera vaccine mali
effect of influenza vaccination on donor egg recipient outcomes

Conditions: Infertility; Recurrent Miscarriage

Summary: in this study the investigators propose a randomized controlled trial to evaluate the effect of influenza vaccination on clinical pregnancy rates among women undergoing in vitro fertilization as donor egg recipients.

since 2004 flu vaccination has been recommended by american college of obstetricians and gynecologists (acog) advisory committee on immunization practices (acip) for all pregnant women during flu season, regardless of the trimester of pregnancy. many studies have examined the safety of influenza vaccination and found benefits beyond the simple prevention of maternal infection including the reduction of still birth. recently evidence has emerged that women who have received a flu vaccination were less likely to experience premature labor. the investigators hypothesize that some of the maternal benefits of influenza vaccination might be based on other than prevention of the flu, possibly secondary to the induction of immune system pathways that favor immunological tolerance. induction of immune system pathways that favor immunological tolerance has long been considered a possible path to improved embryo implantation and reduce miscarriages, though the topic is still somewhat controversial. patients undergoing donor egg recipient cycles will be randomized in two strata: 1. history of recurrent miscarriage or implantation failure 2. no history of recurrent miscarriage of implantation failure consenting patients will be randomized to receive either influenza vaccine or a saline placebo. vaccination will occur 10 days before initiating anticipated menses or fertility treatment cycle start. all patients will be receiving an offered a second injection at the time of negative pregnancy test or at the time of sign-out with a clinical pregnancy. the second injection will either be placebo or influenza vaccination depending on the original randomization. patients and clinical staff will remain blinded to the original treatment assignment, except for the study coordinator and the single staff member assigned to administer the injection.

Eligibility criteria:
inclusion criteria: * all women preparing to undergo an oocyte donor recipient cycle 1. women will only be allowed to participate in one treatment cycle 2. willingness to have an influenza vaccination 3. signed informed consent exclusion criteria: 1. any contraindication for flu vaccination 2. unwillingness to have a flu vaccination 3. unwillingness to sign informed consent 4. previous diagnosis of unfavorable endometrial development 5. unresolved uterine condition that significantly compromises the endometrial cavity

Keywords: immunology pregnancy implantation rate fertilization in vitro oocyte donor egg recipient
study to determine the effectiveness of detrusitol in patients diagnosed with oab

Conditions: Urinary Incontinence

Summary: the purpose of this study is to evaluate the effectiveness of detrusitol (tolterodine tartrate) sr, 4 mg once daily, on patient's perception of the symptoms of overactive bladder and which of these bothersome symptoms are improved with treatment.


Eligibility criteria:
inclusion criteria: * 18 years or older patients suffering from oab symptoms (urinary frequency of at least 8 micturitions per 24h, urinary urgency and at least 3 urge urinary incontinence episodes within 3 days), confirmed by a micturition bladder diary. exclusion criteria: * other than urge incontinence * history of prostate/uterine or other female organ cancer
computed tomography anatomy of the paranasal sinuses and anatomical variants of clinical relevants in egyptian adults .

Conditions: Sinusitis

Summary: the aim of this study is to show the anatomy of the paranasal sinuses as delineated by the computed tomography among egyptian adults and to describe the variants which not only predispose to chronic sinusitis but may lead to complications in endoscopic sinonasal surgery.

the paranasal sinuses are group of air filled spaces surrounding the nasal cavity; which start developing from the primitive choana at 25-28 weeks of gestation.1 three projections arise from the lateral wall of the nose and serve as the beginning of the development of the paranasal sinuses. the anterior projection forms the aggernasi, the inferior or maxiloturbinate projection forms the inferior turbinates and maxillary sinus, while the superior or ethmoidoturbinate projection forms the ethmoidal air cells and their corresponding drainage channels. the sinuses are named from the facial bones in which they are located. the maxillary and ethmoid sinuses are aerated at birth, while the sphenoid sinuses and frontal sinuses are pneumatized at about the 2nd and 6th year of life respectively.1 the sinuses reach the adult size at adolescent age.1 radiologic evaluation of the paranasal sinuses is essential in delineating the location and extent of sinonasal diseases and in planning surgical intervention. plain radiography, computed tomography and magnetic resonance imaging are applied in evaluating the sinuses. standard paranasal sinus radiograph can readily demonstrate the maxillary or frontal sinus diseases but incompletely delineates ethmoid sinus due to overlapping of structures.2 the role of magnetic resonance imaging is limited but may provide information on paranasal sinuses fungal infection and differentiating thickened mucosa from fluid retention. computed tomography is considered the method of choice in delineating completely the normal anatomy and anatomical variants of the paranasal sinuses and it is extremely useful in the pre-operative planning and in post operative follow-up in cases of endonasal interventions. the development of the paranasal sinuses especially the ethmoid labyrinth is associated with anatomical variations.3 some of which are common while others are rare. recognition of these variants is important to both the rhinologist and radiologist. proximity of these occasional cells to the main drainage pathway of the paranasal sinuses may reduce the mucociliary clearance, thus predisposing to inflammatory processes and causing endonasal endoscopic surgery complications.

Eligibility criteria:
inclusion criteria: * all cases of computed tomography scan of the paranasal sinuses obtained in the radiology department of our health institution exclusion criteria: * patients with facial trauma, positive paranasal sinus pathology, head and neck tumours and previous surgery were excluded.